Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 10/20 | 0.43 |
| ▸ | PPARA | Q07869 | 9/20 | 0.43 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8469074 | 0.85 | PPARG (0.51) | PPARGPPARANPC1RAB9ACYP4F2 | |
| SCHEMBL14114075 | 0.80 | KDM4E (0.45) | LOXL2NPC1RAB9ALMNAHTT | |
| SCHEMBL7879528 | 0.80 | KDM4E (0.45) | LOXL2NPC1RAB9ALMNAHTT | |
| SCHEMBL6815084 | 0.79 | NPC1 (0.50) | NPC1RAB9AL3MBTL1 | |
| SCHEMBL6815081 | 0.79 | NPC1 (0.50) | NPC1RAB9AL3MBTL1 | |
| SCHEMBL18645024 | 0.78 | ALDH1A1 (0.45) | NPC1RAB9ALMNAMAPK1HTT | |
| SCHEMBL4622955 | 0.77 | TSHR (0.49) | LOXL2NPC1RAB9ACYP4F2CYP4A11 | |
| SCHEMBL4622952 | 0.77 | TSHR (0.49) | LOXL2NPC1RAB9ACYP4F2CYP4A11 | |
| SCHEMBL6811343 | 0.77 | NPC1 (0.46) | NPC1RAB9AHIF1AHTT | |
| SCHEMBL6811346 | 0.77 | NPC1 (0.46) | NPC1RAB9AHIF1AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090076088-A1 | Thrombin Receptor Antagonists | SCHERING CORPORATION | 2009-03-19 | — | — | US | disclosed |
| US-20090069383-A1 | Thrombin Receptor Antagonists | SCHERING CORPORATION | 2009-03-12 | — | — | US | disclosed |
| US-7488742-B2 | Thrombin receptor antagonists | SCHERING CORPORATION (US) | 2009-02-10 | — | — | US | disclosed |
| US-20040152736-A1 | Thrombin receptor antagonists | TOPROL ACQUISITION LLC | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076088-A1 | Thrombin Receptor Antagonists | CNR1, CNR2, TBXA2R | PPARG 312/4885PPARA 274/4885LOXL2 1424/4885 |
| US-20040152736-A1 | Thrombin receptor antagonists | CNR1, TBXA2R, CNR2 | PPARG 434/4885PPARA 397/4885LOXL2 1469/4885 |
| US-20090069383-A1 | Thrombin Receptor Antagonists | CNR1, CNR2, TBXA2R | PPARG 312/4885PPARA 274/4885LOXL2 1424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.